Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Get Rating) – Investment analysts at SVB Leerink increased their Q1 2022 earnings per share estimates for Jazz Pharmaceuticals in a report issued on Thursday, April 21st. SVB Leerink analyst M. Goodman now forecasts that the specialty pharmaceutical company will earn $2.98 per share for the quarter, up from their previous estimate of $2.85. SVB Leerink also issued estimates for Jazz Pharmaceuticals’ Q2 2022 earnings at $3.78 EPS and Q3 2022 earnings at $3.73 EPS.
Several other research analysts have also commented on JAZZ. The Goldman Sachs Group lowered Jazz Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $202.00 to $196.00 in a research report on Wednesday, April 6th. Truist Financial upped their target price on Jazz Pharmaceuticals from $180.00 to $200.00 in a research report on Thursday, January 20th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Jazz Pharmaceuticals in a research report on Wednesday, March 2nd. Royal Bank of Canada reduced their target price on Jazz Pharmaceuticals from $216.00 to $214.00 and set an “outperform” rating on the stock in a research report on Wednesday, March 2nd. Finally, Piper Sandler cut their price objective on Jazz Pharmaceuticals from $209.00 to $197.00 and set an “overweight” rating on the stock in a report on Wednesday, March 2nd. Three analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $203.92.
Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Rating) last issued its earnings results on Tuesday, March 1st. The specialty pharmaceutical company reported $3.66 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.98 by $0.68. Jazz Pharmaceuticals had a positive return on equity of 21.56% and a negative net margin of 10.65%. The business had revenue of $896.73 million during the quarter, compared to analysts’ expectations of $866.71 million. During the same period in the prior year, the business earned $3.56 EPS. The business’s revenue for the quarter was up 34.7% compared to the same quarter last year.
In related news, CEO Bruce C. Cozadd sold 10,772 shares of the stock in a transaction on Monday, April 4th. The stock was sold at an average price of $158.33, for a total value of $1,705,530.76. Following the transaction, the chief executive officer now directly owns 346,062 shares of the company’s stock, valued at approximately $54,791,996.46. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Bruce C. Cozadd sold 6,372 shares of the stock in a transaction on Tuesday, February 1st. The stock was sold at an average price of $139.23, for a total value of $887,173.56. The disclosure for this sale can be found here. Corporate insiders own 4.30% of the company’s stock.
Large investors have recently added to or reduced their stakes in the business. Goldman Sachs Group Inc. grew its stake in shares of Jazz Pharmaceuticals by 638.0% during the fourth quarter. Goldman Sachs Group Inc. now owns 1,310,729 shares of the specialty pharmaceutical company’s stock valued at $166,987,000 after acquiring an additional 1,133,121 shares in the last quarter. Point72 Asset Management L.P. acquired a new stake in shares of Jazz Pharmaceuticals during the third quarter valued at about $97,566,000. Polaris Capital Management LLC grew its stake in Jazz Pharmaceuticals by 51.8% in the third quarter. Polaris Capital Management LLC now owns 1,962,763 shares of the specialty pharmaceutical company’s stock worth $255,571,000 after purchasing an additional 670,003 shares in the last quarter. Farallon Capital Management LLC acquired a new position in Jazz Pharmaceuticals in the third quarter worth about $74,859,000. Finally, Norges Bank acquired a new position in Jazz Pharmaceuticals in the fourth quarter worth about $71,557,000. 91.95% of the stock is currently owned by institutional investors.
About Jazz Pharmaceuticals (Get Rating)
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors.
- Get a free copy of the StockNews.com research report on Jazz Pharmaceuticals (JAZZ)
- Should You Buy Carvana or AutoNation or Pass on Both?
- MarketBeat Podcast: 3 Stocks Flashing Buy Signals
- What Should Investors Take Away From Boston Beer’s Earnings?
- High-Yield Kinder Morgan Is Still A Buy
- NextEra Energy Offers a Long-Term Gain if You Can Tolerate Short-Term Pain
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.